1. The European Association for Clinical Pharmacology and Therapeutics—25 years’ young and going strong

   • Jamie J. Coleman
   • Caroline Samer
   • Ylva Böttiger

   Special Article Open access 16 May 2019 Pages: 743 - 750

   

2. Impact of drugs on venous thromboembolism risk in surgical patients

   • Alenka Premuš Marušič Kovačič
   • Martin Caprnda
   • Danijel Petrovič

   Review 05 February 2019 Pages: 751 - 767

   

3. The evidence-based choice for antipsychotics in children and adolescents should be guaranteed

   • Daria Putignano
   • Antonio Clavenna
   • Maurizio Bonati

   Review 07 February 2019 Pages: 769 - 776

4. Metamizole inhibits arachidonic acid-induced platelet aggregation after surgery and impairs the effect of aspirin in hospitalized patients

   • C. Pfrepper
   • S. Deters
   • S. Petros

   Clinical Trial 18 February 2019 Pages: 777 - 784

   

5. Relationship between warfarin dosage and international normalized ratio: a dose–response analysis and evaluation based on multicenter data

   • Ling Xue
   • Yuzhen Zhang
   • Liyan Miao

   Pharmacodynamics 29 April 2019 Pages: 785 - 794

   

6. IL-2 gene polymorphisms affect tacrolimus response in myasthenia gravis

   • Yang Shumei
   • Li Yi
   • Yang Huan

   Pharmacogenetics 07 February 2019 Pages: 795 - 800

   

7. Sex-by-formulation interaction in bioequivalence trials with transdermal patches

   • Esperanza González-Rojano
   • Julio Marcotegui
   • Alfredo García-Arieta

   Pharmacokinetics and Disposition 06 February 2019 Pages: 801 - 808

   

8. Dried blood spot testing for estimation of renal function and analysis of metformin and sitagliptin concentrations in diabetic patients: a cross-sectional study

   • Maike Scherf-Clavel
   • Edwin Albert
   • Petra Högger

   Pharmacokinetics and Disposition 31 January 2019 Pages: 809 - 816

   

9. Downregulation of ABCB1 gene in patients with total hip or knee arthroplasty influences pharmacokinetics of rivaroxaban: a population pharmacokinetic-pharmacodynamic study

   • Jurij Zdovc
   • Maja Petre
   • Iztok Grabnar

   Pharmacokinetics and Disposition 06 February 2019 Pages: 817 - 824

   

10. Feasibility of and patients’ perspective on nilotinib dried blood spot self-sampling

    • Christel C. L. M. Boons
    • Lonneke Timmers
    • N. Harry Hendrikse

    Pharmacokinetics and Disposition Open access 07 February 2019 Pages: 825 - 829

11. Monitoring of tobramycin serum concentrations in selected critically ill patients receiving selective decontamination of the digestive tract: a retrospective evaluation

    • J. E. Möhlmann
    • M. van Luin
    • M. R. de Maat

    Pharmacokinetics and Disposition 18 February 2019 Pages: 831 - 836

    

12. Is there a potential association between spironolactone and the risk of new-onset diabetes in a cohort of older patients with heart failure?

    • Sandra Korol
    • Michel White
    • Sylvie Perreault

    Pharmacoepidemiology and Prescription 13 February 2019 Pages: 837 - 847

    

13. Fall-risk-increasing adverse reactions—is there value in easily accessible drug information? A case-control study

    • Susanne Schiek
    • Katja Hildebrandt
    • Thilo Bertsche

    Pharmacoepidemiology and Prescription 13 February 2019 Pages: 849 - 857

14. Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment

    • Toshinori Hirai
    • Kazuhiko Hanada
    • Toshimasa Itoh

    Pharmacoepidemiology and Prescription 15 February 2019 Pages: 859 - 866

15. Correction to: Risk factors for vancomycin nephrotoxicity and time course of renal function during vancomycin treatment

    • Toshinori Hirai
    • Kazuhiko Hanada
    • Toshimasa Itoh

    Correction 19 March 2019 Pages: 867 - 867

16. Severe reduction in tacrolimus concentrations with concomitant metamizole (dipyrone) therapy in transplant patients

    • Ali Sigaroudi
    • Alexander Jetter
    • Stefan Weiler

    Letter to the Editor 29 January 2019 Pages: 869 - 872

    

17. Is an elevated burden of antiarrhythmic drug (AAD) side-effects the unavoidable price to be traded for a durable suppression of AF relapses in ablated patients? The weaknesses and risks of the AAD suppression algorithm used by current models of AF secondary prevention after catheter ablation

    • Renato De Vecchis

    Letter to the Editor 29 January 2019 Pages: 873 - 874

18. Dabigatran levels in omeprazole versus pantoprazole-treated patients with atrial fibrillation: is there a difference?

    • Tomáš Bolek
    • Matej Samoš
    • Marián Mokán

    Letter to the Editor 12 February 2019 Pages: 875 - 877